Summary: Researchers have identified a promising new drug target for treating Fragile X syndrome, the most common genetic cause of autism and intellectual disability. The study reveals that a single-gene mutation (FMR1) induces an abnormal, widespread increase of a synapse-localized protein called EPAC2 across multiple brain cell types.
By blocking this protein either genetically or with a drug compound in mouse models, scientists successfully corrected disrupted brain circuit activity and reversed core behavioral symptoms, including hypersensitivity to touch, social interaction deficits, and seizure susceptibility.
Key Facts
- The Single-Gene Root: Fragile X syndrome stems from a mutation in the $FMR1$ gene, which halts the production of a protein vital for typical brain development. It affects approximately 1 in 2,000 boys.
- The EPAC2 Discovery: Using RNA sequencing on genetically engineered mice missing the FMR1 gene, researchers discovered that expression of the $EPAC2$ gene, which encodes a protein critical for learning and memory, was abnormally elevated at the synapses.
- Cellular System Rebalancing: Fragile X is believed to be driven by an imbalance between excitatory and inhibitory brain cells. While the FMR1 mutation alters these two cell types differently, EPAC2 was consistently elevated across both systems, making it an ideal therapeutic anchor.
- High Brain Specificity: Because the EPAC2 protein is expressed almost exclusively within the brain, developing a drug compound to block it carries a significantly lower risk of causing adverse, unwanted side effects elsewhere in the body.
- Broad Lifespan Relevance: The study noted that EPAC2 levels climb gradually as the brain matures, suggesting that therapies targeting this protein could be highly effective for older children and adults, rather than being limited to a narrow early-development window.
Source: UCLA
UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly 1 in 2,000 boys.
Fragile X syndrome is caused by a mutation in a single gene, FMR1, that results in the loss of a protein critical for normal brain development and function. People with the condition commonly experience intellectual disability, difficulty with attention and social interaction, heightened sensitivity to sensory input such as sound and touch, and a higher risk of seizures. Many also meet the criteria for an autism spectrum disorder diagnosis.
As it is caused by a change in a single gene, Fragile X has long been considered a promising candidate for targeted therapies yet clinical trials to date have not produced an effective treatment.
In the new study published in Neuron, researchers used genetically engineered mice that are missing the FMR1 gene to simulate Fragile X syndrome. Using genetic sequencing, they found that levels of the gene EPAC2 were increased in the brain of Fragile X mice. This was of potential interest as a target for therapy because the protein, also called EPAC2, is localized to synapses and is known to be important for learning and memory.
The researchers then demonstrated that blocking EPAC2 in the Fragile X mouse model restored abnormal patterns of brain activity and improved several behavioral symptoms associated with Fragile X syndrome including heightened sensitivity to touch, difficulties with social interaction and their susceptibility for seizures.
“EPAC2 emerged as an attractive target because it was consistently altered across multiple types of brain cells in our analysis,” said the study’s lead author Dr. Anand Suresh, a post-doctoral fellow in the laboratory of Dr. Carlos Portera-Cailliau, professor of neurology at UCLA and member of the UCLA Brain Research Institute.
“When we blocked it, either genetically or with a drug compound, we saw meaningful improvements in both brain circuit function and behavior.”
EPAC2 is expressed almost exclusively in the brain, which means drugs targeting it are less likely to cause unwanted effects elsewhere in the body. Suresh said this is an important consideration as researchers continue preclinical studies.
To reach this finding, UCLA researchers used an RNA sequencing technique to examine gene activity separately in two major classes of brain cells: those that excite and those that inhibit neural activity. Fragile X syndrome is thought to arise from an imbalance between these two systems.
The analysis revealed striking differences in how the genetic mutation underlying Fragile X syndrome affects each cell type but also identified a small set of genes, including the one that encodes EPAC2, that were dysregulated in both.
The researchers also found that EPAC2 levels appear to rise gradually as the brain matures, suggesting it may be a particularly relevant target for older children and adults with Fragile X syndrome, rather than only in early development.
Key Questions Answered:
A: While Fragile X has long been considered a prime candidate for targeted gene therapies, translating that concept into clinical trials has proven incredibly difficult, and no effective treatments exist yet. Instead of trying to fix the missing FMR1 gene directly, the UCLA team looked downstream to find out what happens when that gene is gone. They found that blocking an overactive protein called EPAC2 completely bypasses the root mutation to fix the brain’s actual wiring.
A: It satisfies two massive clinical criteria: safety and uniformity. First, the FMR1 mutation disrupts excitatory and inhibitory brain cells in wildly different, messy ways, but EPAC2 was one of the rare proteins consistently elevated in both cell types. Second, because EPAC2 is almost exclusively found in the brain, any drug designed to block it won’t trigger dangerous side effects in the rest of the body’s organs.
A: Surprisingly, no. The researchers discovered that EPAC2 levels actually rise gradually as the brain matures over time. This is a massive breakthrough because it indicates that an EPAC2-blocking medication wouldn’t rely on a restrictive, early-childhood developmental window, it could provide profound cognitive and behavioral relief for older children, teenagers, and adults who are already living with the condition.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Fragile X syndrome research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target” by Anand Suresh, Nazim Kourdougli, Toshihiro Nomura, Jessie E. Buth, Soledad Miranda-Rottmann, Carlos A. Sánchez-León, Michelle W. Wu, Sofia M. Nelson, Lauren T. Wall, Anne T. Tran, Roberto Araya, Anis Contractor, Michael J. Gandal, and Carlos Portera-Cailliau. Neuron
DOI:10.1016/j.neuron.2026.04.032
Abstract
Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target
Symptoms of fragile X syndrome (FXS), the leading monogenic cause of intellectual disability and autism, are thought to arise from an excitation/inhibition (E/I) imbalance.
Here, we leverage cell-type-specific mRNA sequencing to profile molecular alterations in cortical excitatory (Camk2) and inhibitory (Pvalb) neurons in Fmr1 knockout (KO) mice, integrating transcriptomic results with circuit and behavioral readouts to prioritize novel therapeutic targets.
We uncovered significant genotype-by-cell type interactions for differential gene expression in Camk2a and Pvalb translatomes, and, strikingly, the underlying signaling pathways were often altered in opposite directions.
Among the 184 differentially expressed genes that were concordantly dysregulated across both cell types, only Rapgef4 (a.k.a., exchange protein direftly activated by cAMP 2 [Epac2]; upregulated in Fmr1 KO) was also a fragile X messenger ribonucleoprotein (FMRP) target, brain-enriched, and associated with neurodevelopmental disorders.
Treatment of Fmr1 KO mice with a specific EPAC2 antagonist restored cortical circuit function and ameliorated multiple behavioral phenotypes.
Thus, EPAC2 should be considered a potential therapeutic target for FXS.
